Lyell Immunopharma Past Earnings Performance
Past criteria checks 0/6
Lyell Immunopharma's earnings have been declining at an average annual rate of -2.6%, while the Biotechs industry saw earnings growing at 22.1% annually. Revenues have been growing at an average rate of 13.7% per year.
Key information
-2.6%
Earnings growth rate
91.0%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | 13.7% |
Return on equity | -38.4% |
Net Margin | -323,792.1% |
Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth
Oct 25Lyell Immunopharma: Testing The T-Cell Thesis With 2 Upcoming Data Catalysts
Apr 16Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Feb 23Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Nov 09Analysts' Revenue Estimates For Lyell Immunopharma, Inc. (NASDAQ:LYEL) Are Surging Higher
Aug 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Aug 11Lyell Immunopharma (NASDAQ:LYEL) Is In A Good Position To Deliver On Growth Plans
Dec 15Lyell Immunopharma gets FDA nod to start phase 1 trial of its cancer therapy LYL845
Oct 06Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Sep 12News Flash: Analysts Just Made A Huge Upgrade To Their Lyell Immunopharma, Inc. (NASDAQ:LYEL) Forecasts
Aug 08Companies Like Lyell Immunopharma (NASDAQ:LYEL) Are In A Position To Invest In Growth
Apr 29We Think Lyell Immunopharma (NASDAQ:LYEL) Can Afford To Drive Business Growth
Dec 31Here's Why We're Not Too Worried About Lyell Immunopharma's (NASDAQ:LYEL) Cash Burn Situation
Sep 17Revenue & Expenses Breakdown
How Lyell Immunopharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Sep 24 | 0 | -204 | 51 | 170 |
30 Jun 24 | 0 | -210 | 54 | 174 |
31 Mar 24 | 0 | -228 | 61 | 181 |
31 Dec 23 | 0 | -235 | 67 | 183 |
30 Sep 23 | 49 | -190 | 80 | 174 |
30 Jun 23 | 48 | -209 | 91 | 172 |
31 Mar 23 | 84 | -182 | 102 | 168 |
31 Dec 22 | 85 | -183 | 117 | 159 |
30 Sep 22 | 39 | -258 | 123 | 140 |
30 Jun 22 | 42 | -237 | 118 | 130 |
31 Mar 22 | 9 | -263 | 107 | 133 |
31 Dec 21 | 11 | -250 | 89 | 139 |
30 Sep 21 | 10 | -205 | 72 | 154 |
30 Jun 21 | 8 | -192 | 59 | 153 |
31 Mar 21 | 9 | -230 | 52 | 201 |
31 Dec 20 | 8 | -208 | 47 | 182 |
31 Dec 19 | 1 | -131 | 39 | 64 |
Quality Earnings: LYEL is currently unprofitable.
Growing Profit Margin: LYEL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: LYEL is unprofitable, and losses have increased over the past 5 years at a rate of 2.6% per year.
Accelerating Growth: Unable to compare LYEL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: LYEL is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: LYEL has a negative Return on Equity (-38.44%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2024/12/24 03:54 |
End of Day Share Price | 2024/12/24 00:00 |
Earnings | 2024/09/30 |
Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package | Data | Timeframe | Example US Source * |
---|---|---|---|
Company Financials | 10 years |
| |
Analyst Consensus Estimates | +3 years |
|
|
Market Prices | 30 years |
| |
Ownership | 10 years |
| |
Management | 10 years |
| |
Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Lyell Immunopharma, Inc. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst | Institution |
---|---|
Geoffrey Meacham | BofA Global Research |
Jason Zemansky | BofA Global Research |
Salveen Richter | Goldman Sachs |